CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $948,923 | -17.6% | 20,906 | +1.9% | 0.51% | -18.7% |
| Q2 2023 | $1,151,712 | +27.6% | 20,515 | +2.8% | 0.63% | +19.7% |
| Q1 2023 | $902,655 | +14.5% | 19,957 | +2.9% | 0.53% | +3.5% |
| Q4 2022 | $788,122 | -35.6% | 19,388 | +3.5% | 0.51% | -37.6% |
| Q3 2022 | $1,224,000 | +8.7% | 18,726 | +1.0% | 0.82% | -3.8% |
| Q2 2022 | $1,126,000 | -2.0% | 18,536 | +1.2% | 0.85% | +21.1% |
| Q1 2022 | $1,149,000 | -16.6% | 18,310 | +0.8% | 0.70% | -9.3% |
| Q4 2021 | $1,377,000 | -33.1% | 18,165 | -1.2% | 0.77% | -33.6% |
| Q3 2021 | $2,057,000 | -32.1% | 18,379 | -1.8% | 1.16% | -31.9% |
| Q2 2021 | $3,028,000 | +33.0% | 18,707 | +0.1% | 1.71% | +17.0% |
| Q1 2021 | $2,277,000 | -20.9% | 18,687 | -0.5% | 1.46% | -28.5% |
| Q4 2020 | $2,877,000 | – | 18,790 | – | 2.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |